A macromolecular prodrug strategy for combinatorial drug delivery
Nan-Nan Li1, Jiantao Lin2, Di Gao1
1DSAPM Lab and PCFM Lab, Department of Polymer and Materials Science, School of Chemistry and Chemical Engineering, Sun Yat-sen University, Guangzhou 510275, China.
Journal of Colloid and Interface Science
|January 11, 2014
Summary
This study introduces a novel macromolecular prodrug for delivering dexamethasone and doxorubicin. The prodrug micelles show effective cellular uptake and significant antitumor activity.
Area of Science:
- Biomaterials Science
- Drug Delivery
- Nanotechnology
Background:
- Poor water solubility of potent anticancer drugs like doxorubicin and anti-inflammatory agents like dexamethasone limits their therapeutic efficacy.
- Combinatorial drug delivery strategies are needed to enhance treatment outcomes for complex diseases.
- Developing advanced drug delivery systems is crucial for improving drug solubility and targeted release.
Purpose of the Study:
- To develop a novel macromolecular prodrug for the co-delivery of dexamethasone and doxorubicin.
- To create self-assembling polymeric micelles for enhanced drug solubility and controlled release.
- To evaluate the cellular internalization and antitumor efficacy of the developed prodrug micelles.
Main Methods:
- Conjugation of dexamethasone to a modified polysaccharide via an acid-labile hydrazone linkage.
- Self-assembly of the amphiphilic prodrug into spherical polymeric micelles in an aqueous system.
- Encapsulation of doxorubicin into the hydrophobic cores of the polymeric micelles.
- Assessment of drug release kinetics under acidic conditions.
- Evaluation of cellular uptake and in vitro antitumor activity.
Main Results:
- Successful synthesis of a macromolecular prodrug with amphiphilic properties.
- Formation of stable, spherical polymeric micelles capable of encapsulating doxorubicin.
- Demonstration of independent and acid-sensitive release of both dexamethasone and doxorubicin.
- Significant cellular internalization of the doxorubicin-loaded prodrug micelles.
- Obvious in vitro antitumor activity observed for the prodrug micelles.
Conclusions:
- The developed macromolecular prodrug strategy enables efficient combinatorial delivery of poorly soluble drugs.
- Polymeric micelles serve as effective nanocarriers for simultaneous drug delivery and controlled release.
- The prodrug micelles exhibit promising potential for cancer therapy due to enhanced cellular uptake and potent antitumor effects.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
01:30Prodrugs
4.1K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
4.1K
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
01:19Modified-Release Drug Delivery Systems: Overview
236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236